

Goldman Sachs

47th Annual Global Healthcare Conference

June 10, 2026

Jim Clemmer, President & CEO

Stephen Trowbridge, Executive Vice President & CFO

Forward looking statements



Notice Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2025. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported pro forma results, adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.



Our proven success positions us for sustained growth and profitability in key markets.

2020 - Today

Drove Performance and Built a More Dynamic Growth Focused Company

Sharpened Portfolio Focus

- Active portfolio management to scale high-growth MedTech opportunities


Accelerated Innovation

- Expanded MedTech leadership through innovation, strategic M&A, clinical investment, and meaningful physician engagement

Strengthened Financial Position

- Delivered accelerated growth, streamlined operations, and improved margin performance

Med Tech Growth & Sales Mix (%)



Today & Beyond

Positioned for Sustained Profitable Growth

Accelerating Commercial Investment

- Building a stronger go-to-market engine in Cardiovascular and Prostate to capture growth opportunities

Fueling Innovation

- Increasing R&D investment to deliver breakthrough technologies and long-term value

Expanding Market Potential

- Growing TAM as clinical data unlocks new indications across MedTech franchises

Robust Product Pipeline


- Leveraging leading platforms to accelerate innovation and support sustained expansion in attractive, high-growth markets



Unrivaled Innovation



Our synergistic portfolio is focused on providing comprehensive solutions to help treat patients within two of the largest global healthcare markets




Cardiovascular Arterial



Since its launch in September 2020, Auryon has been used in nearly 150,000 procedures and surpassed \$200M in cumulative sales

MARKET DYNAMICS



Peripheral Artery Disease (PAD)

- Hospital market growth fuels ASP stability
- New and expanded reimbursement coverage solidifies atherectomy's place in treatment algorithms
- AMBITION BTK further positions us for market expansion

Auryon is versatile and effective at treating all types of lesions both through the femoral and radial approaches

Comprehensive Treatment Capability

- Effectively addresses all lesion types, including severe calcification and in-stent restenosis

Precision and Safety

- Optimized technology delivers energy without thermal damage, with built-in aspiration to minimize embolization risk

Efficiency and Proven Outcomes

- Portable, easy-to-use system with clinically validated performance and high patency rates




AURYON

Cardiovascular Venous



Venous Thromboembolism (VTE) represents an attractive, high growth, underpenetrated market opportunity

MARKET DYNAMICS




PE + DVT = Venous Thromboembolism (VTE)

- Mechanical Thrombectomy for **PE** is estimated to have penetrated ~20% of the TAM
- Mechanical Thrombectomy for **DVT** is estimated to have penetrated ~15% of the TAM

Right Heart Cardiac Thrombus & Emboli

- Growth is driven by rising increase in endocarditis and an aging population
- More interventionalists embrace percutaneous techniques and the structural heart market is expanding

ANGIOVAC



ALPHAVAC



Mechanical Thrombectomy



Proprietary funnel cannula technology with the ability to have aspiration and simultaneous reinfusion with AngioVac or off-circuit manual aspiration control with AlphaVac

AlphaVac Indicated for Treatment of Pulmonary Embolism


Aspiration & Simultaneous Reinfusion



- Minimally invasive treatment used to treat PE and remove large blood clots, or thrombi, and other material from the venous system (veins), including the pulmonary arteries
- Manual aspiration control enables precise suction, enhanced physician control, and improved maneuverability for wireless navigation between the PA's



- Minimally invasive treatment used to remove large blood clots, or thrombi, and other material from the venous system (veins)
- On-circuit aspiration provides surgical results via percutaneous access by simultaneously reinfusing blood back in the patient's body, minimizing blood loss



Complete system significantly improving reduction in clot burden vs. competitive technologies



*Actual case result

APEX – AV Pivotal Study



AlphaVac received FDA clearance for PE following APEX-AV study demonstrating efficacy and significantly improved reduction in clot burden vs. competitive technologies

A P E X - A V

Number of Sites	25 US Sites
Number of Patients	122
Timeline	Oct. 2022 – Dec 2023

Significant reduction in the RV/LV ratio

- Significant improvement in the RV function

Significant reduction in clot burden

- Large funnel size (33 Fr) may aid in reducing the clot burden

Procedure efficiency

- Atraumatic tip provides easy and efficient navigation in the PAs
- Ability to minimize blood loss
- Short procedure time


	APEX (AngioDynamics)	FLARE (Inari/Stryker)	EXTRACT-PE (Penumbra)
Reduction in Clot Burden	35.1%	9.3%	11.3%

Prostate Cancer



Backed by real world evidence and compelling clinical data, NanoKnife is a one-of-a-kind technology poised to change the standard of care of men with prostate cancer

MARKET DYNAMICS




Prostate Cancer is Prevalent, On the Rise & Debilitating

- The most diagnosed male cancer in 112 countries, including the U.S.
- Incidence projected to double by 2040
- Focal therapy is less than 7% penetrated into the Intermediate Risk addressable market

Only Function-preserving Therapy that Uses Electricity to Destroy Prostate Tumors

- Destroys targeted tissue with precise margins, preserving vital structures and tissue integrity
- Backed by real world evidence and compelling clinical data, NanoKnife is a one-of-a-kind technology poised to change the standard of care of men with prostate cancer
- NanoKnife safely & effectively treats prostate tumors while avoiding the high incidence of erectile dysfunction and incontinence associated with radical surgery and radiation

NANOKNIFE
Irreversible Electroporation (IRE) PROSTATE



Irreversible Electroporation (IRE)



Preserves the underlying structure of tissue giving physicians a more precise tool



Only IRE device FDA cleared for prostate tissue



Efficiently treats all segments of the prostate

Easy clinical integration

Significantly reduces quality of life side-effects caused by other therapeutic options


PROBE PLACEMENT

NanoKnife can be confidently used in all segments of an organ.



DECELLULARIZATION

Destroys targeted tissue with precise treatment margins.



NON-THERMAL

Spares vital structures by retaining the structural integrity of tissue.³



REVASCULARIZATION

Facilitates functional tissue regeneration post-ablation.

PRESERVE Pivotal Study



NanoKnife safely & effectively treats prostate tumors while avoiding the high incidence of erectile dysfunction and incontinence associated with radical surgery and radiation

PRESERVE

Number of Sites **17 US Sites**
Number of Patients **121**
Follow Up **12 Months**

Efficacy

84% of patients were free from clinically significant in-field disease

Safety

3.3% of patients had a device related SAE, all of which resolved

Change from baseline at 1 year

	IRE	Radical Surgery	Radiation Therapy
Erectile Function	(9%)	(51%)	(30%)
Urinary Continence	(1.2%)	(41%)	(8%)

We will continue to follow patients in PRESERVE study and collect data

National Recognition for Oncology



Leveraging TIME and AARP to elevate awareness and credibility

TIME's Best Inventions of 2025

AARP Marketing Partnership



- Recognized as a top innovation in Medical & Healthcare
- Highlights AngioDynamics' leadership in minimally invasive oncology
- National visibility and validation of our breakthrough technology

BRANDAMP BY AARP PAID CONTENT NANOKNIFE

A NEW WAY FORWARD IN PROSTATE TUMOR CARE

Preserve Your Health and Quality of Life

Chances are, you know someone who's had prostate cancer, since it's one of the most common cancers diagnosed in men around the world. In fact, 1 in 8 men will be diagnosed with prostate cancer.¹ Many men experience fear around the diagnosis as well as the implications of treatment – which is understandable. Previously, patients had to choose between radical surgery or radiation that may negatively impact erectile and urinary function.^{2,3,4} Today, a new technology is expanding the treatment options available to men.

Science at Work

The NanoKnife System is the only minimally invasive therapy that precisely targets the prostate tumor with electrical pulses, destroying cells while helping to preserve sexual function and urinary continence.⁵

- **Fast and Efficient** – an outpatient procedure that takes about an hour and has a rapid recovery time⁶
- **Safe and Effective** – helps preserve urinary control and erectile function⁷
- **Conserve Future Options** – procedure can be repeated if necessary and does not interfere with other treatment options⁸

What to Expect

The NanoKnife System therapy is an outpatient procedure performed under general anesthesia by specially-trained urologic surgeons at a hospital or ambulatory surgery center. Thin, minimally invasive needles will be placed around the tumor, electrical pulses are delivered between the needles, destroying the prostate tumor. Post-procedure recovery will vary, but expect a catheter to remain for a few days. Follow-up visits will confirm the effectiveness of treatment. If the NanoKnife System is right for you, then your doctor will provide you with detailed information related to your procedure.

Wondering if the NanoKnife System is a good option for you or your loved one?

The ideal candidate has prostate tumors visible on imaging. Consult with a specialist who has experience with the NanoKnife System. Insurance coverage can vary depending on your provider. There's a different way forward, don't let fear of treatment or side effects hold you back.

Take the next step. Use the physician locator at NanoKnife.com/AARP to find a NanoKnife doctor near you.

AARP does not recommend individual healthcare providers

Meet Paul

"I was playing golf a week and a half after I had the procedure. I was able to walk and swing the same way I was swinging... just like I never had the procedure." – Paul


Scan the QR code to watch video and see how the NanoKnife Procedure works.

1. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed May 13, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. 3. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 4. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 5. Galshten M, Galshten S, Bismuth A, et al. Modulation of urinary continence and sexual function by minimally-invasive electroresection for localized prostate cancer. *BJU Int*. 2012;110:111-116. 6. George AJ, Mironovs R, Patel AJ, et al. Invasiveness Electroresection for Prostate: Three Adjunctive Patients with Improved Quality of Life. *Prostate Cancer*. 2019;2019:1-7. 7. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 8. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 9. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 10. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 11. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 12. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 13. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 14. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 15. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 16. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 17. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 18. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 19. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 20. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 21. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 22. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 23. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 24. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 25. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 26. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 27. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 28. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 29. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 30. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 31. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 32. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 33. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 34. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 35. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 36. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 37. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 38. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 39. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 40. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 41. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 42. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 43. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 44. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 45. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 46. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 47. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 48. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 49. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 50. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 51. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 52. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 53. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 54. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 55. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 56. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 57. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 58. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 59. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 60. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 61. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 62. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 63. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 64. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 65. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 66. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 67. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 68. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 69. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 70. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 71. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 72. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 73. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 74. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 75. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 76. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 77. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 78. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 79. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 80. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 81. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 82. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 83. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 84. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 85. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 86. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 87. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 88. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 89. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 90. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 91. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 92. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 93. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 94. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 95. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 96. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 97. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 98. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 99. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 100. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 101. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 102. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 103. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 104. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 105. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 106. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 107. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 108. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 109. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 110. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 111. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 112. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 113. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 114. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 115. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 116. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 117. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 118. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 119. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 120. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 121. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 122. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 123. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 124. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 125. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 126. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 127. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 128. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 129. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 130. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 131. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 132. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 133. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 134. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 135. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 136. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 137. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 138. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 139. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 140. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 141. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 142. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 143. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 144. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 145. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 146. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 147. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 148. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 149. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 150. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 151. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 152. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 153. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 154. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 155. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 156. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 157. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 158. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 159. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 160. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 161. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 162. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 163. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 164. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 165. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 166. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 167. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 168. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 169. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 170. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 171. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 172. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 173. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 174. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 175. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 176. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 177. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 178. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 179. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 180. <https://www.aacr.org/news/2019/prostate-cancer-statistics/>. Accessed 10/20/2020. 181. [https://www](https://www.aacr.org/news/2019/prostate-cancer-statistics/)

Strong Product & Clinical Pipeline



Leveraging our leading platforms to fuel innovation, market expansion, and long-term shareholder value in key growth markets






Q3 FY 2026 Key Takeaways

Continued commercial and operational execution drives AngioDynamics' accelerated and profitable growth.

Continued Commercial Execution – Q3 FY 2026



Continued Execution

- Net sales of \$78.4M, +8.9% YoY growth
- Med Tech segment sales of \$37.3M, +19.0% YoY growth
- Med Device segment sales of \$41.1M, +1.1% YoY growth

Focus on Profitability

- Pro forma Adjusted EBITDA** of \$1.8M, an improvement of \$0.5M from Q3 FY 2025

Balance Sheet Strength


- Ended quarter with \$37.8M in Cash
- Zero debt with flexibility of revolving line of credit
- Used ~\$3.0M of cash in the quarter, slightly better than previously guided

Compelling FY 2026 Financial Outlook

supported by balance sheet strength



FY 2026 Net Sales (\$M)



FY 2026 Financial Guidance*

Metric	Action	Current Guidance	Prior Guidance
Net Sales	Increased	\$313.5 - \$315.5M	\$312 - \$314M
<i>Med Tech Net Sales Growth</i>	<i>Increased</i>	<i>+15% - 17%</i>	<i>+14 - 16%</i>
<i>Med Device Net Sales Growth</i>	<i>Increased</i>	<i>Approx. 1%</i>	<i>+0 - 1%</i>
Gross Margin	Unchanged	53.5 - 55.5%	53.5 - 55.5%
Adjusted EBITDA	Increased	+\$10.0 - \$12.0M	+\$8.0 - \$10.0M
Adjusted EPS	Increased	(\$0.30) - (\$0.23)	(\$0.33) - (\$0.23)

- **FY 2026 Cash Guidance:** Proactively increasing inventory may result in additional cash use in Q4, bringing full-year operating cash to slightly negative, down from prior positive guidance.
- **\$37.8M** in Cash at Feb 28, 2026
- **Zero debt on balance sheet with flexibility** from revolving line of credit

AngioDynamics Investment Summary



Attractive MedTech Platforms in High-Value Markets

Our MedTech segment operates in large, growing clinical markets, supported by differentiated technologies and proven clinical outcomes.

Demonstrated Execution and Portfolio Discipline

We have a strong track record of active portfolio management, disciplined R&D investment, successful clinical and regulatory expansion, and customer-centric sales and marketing execution.

Self-Funded Growth Model

Our Med Device segment generates cash flow that funds targeted investments to accelerate MedTech innovation and growth.

Strong, Debt-Free Balance Sheet

We maintain a solid financial foundation with no debt, providing flexibility to invest, scale, and pursue strategic opportunities.

Clear Path to Profitability and Cash Generation

We achieved adjusted EBITDA positivity by FY2025 and are approaching cash flow positivity in FY2026, reflecting improving operating leverage and margin expansion.

Positioned for Sustainable, Long-Term Value Creation

With focused strategy, financial strength, and innovation-driven growth, AngioDynamics is well positioned to deliver durable revenue growth and profitability over the long term.